Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VectivBio to Participate at the Bank of America 2022 Healthcare Conference

VECT

BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV. Company management will also be participating in one-on-one investor meetings at the conference on Wednesday, May 11, 2022.

Bank of America 2022 Healthcare Conference
Date: Wednesday, May 11, 2022
Time: 4:40 p.m. PT / 7:40 p.m. ET
Webcast: Click here

An archived replay of the webcast will be available for 30 days following the presentation and will be accessible through the Events and Presentations section of VectivBio’s website at www.vectivbio.com.

About VectivBio AG
VectivBio (Nasdaq: VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Our lead product candidate, apraglutide, is a next-generation GLP-2 analog currently in a global Phase 3 clinical trial for short bowel syndrome with intestinal failure (SBS-IF). It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).

With the CoMET platform, VectivBio aims to address severe and often fatal Inherited Metabolic Diseases (IMDs) in pediatric populations. IMDs represent a group of genetic disorders in which dysregulated Co-enzyme A (CoA) metabolism is a factor. Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA). Additional targets include urea cycle disorders, fatty acid oxidation disorders, and amino acidopathies.

Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.

Contact:
Patrick Malloy
VectivBio SVP, Investor Relations and Strategic Communications
Patrick.Malloy@vectivbio.com


Primary Logo